Chronic pain clinical trials in Sarnia, Ontario

Name: Chronic pain clinical trials in Sarnia
Creator: Chronic Pain Canada

Part of chronic pain trials in Ontario.

Trials

Recruiting or not yet

Trial sites

Trials with a site in Sarnia

11 trials, recruiting first

		Phase
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain NCT07035093	Active, not recruiting	Phase 3	Eli Lilly and Company	2025-05-29
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy NCT06568042	Completed	Phase 2	Eli Lilly and Company	2024-08-22
A Phase 3 Study of Tanezumab for Chronic Low Back Pain NCT02528253	Completed	Phase 3	Pfizer	2015-08-18
Long Term Safety of Naldemedine NCT01965652	Completed	Phase 3	Shionogi	2013-09-24
A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis NCT01094262	Terminated	Phase 2	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2010-04-20
A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy NCT01041859	Completed	Phase 3	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2009-12
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain NCT00973141	Terminated	Phase 2	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2009-09-16
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain NCT00973024	Terminated	Phase 2	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2009-09
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain NCT00487435	Completed	Phase 3	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2007-06
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain NCT00361504	Completed	Phase 3	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2006-11
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use" NCT00139776	Completed	Phase 4	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2005-07

Facilities listed in the registry

Bluewater Clinical Research Group Inc. (2 trial sites)
Shionogi Research Site (1 trial site)
Pfizer Investigational Site (1 trial site)
London Road Diagnostic Clinic & Medical Centre (1 trial site)

Facility names are as entered by study registrants. This is not a clinic directory.

Map

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status.